RCS - Avacta Group PLC - Private Shareholder Update Event <Origin Href="QuoteRef">AVTG.L</Origin>
RNS Number : 9378TAvacta Group PLC19 October 201719 October 2017
Avacta Group plc
("Avacta" or "the Company")
Private Shareholder Update Event
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, will be hosting a Private Shareholder event on Wednesday, 15 November 2017 at 2.00 pm until 4.00 pm at finnCap's offices, 60 New Broad St, London EC2M 1JJ and will take the form of a Company presentation to update shareholders on progress followed by a Q&A session.
The presentation for the event will also be made available on the Company's website.
Investors and shareholders who wish to attend the event should register their interest at:
- Ends -
For further information from Avacta Group plc, please contact:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Tel: +44 (0) 844 414 0452
finnCap Ltd
Geoff Nash / Giles Rolls - Nominated Adviser
Tim Redfern / Alice Lane / Nikita Jain - Corporate Broking
WG Partners
Nigel Birks / Nigel Barnes
David Wilson / Claes Spang
Tel: +44 (0) 207 220 0500
www.finncap.com
Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Yellow Jersey (Financial Media and IR)
Sarah Hollins
Tel: +44 (0)7787 502 947
katie.odgaard@zymecommunications.com
Tel: +44 (0)7764 947137
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
This information is provided by RNSThe company news service from the London Stock ExchangeENDNRAGGGRWUUPMURR
Recent news on Avacta
See all newsREG - Avacta Group PLC - Avacta Reports Data at the AACR Annual Meeting
AnnouncementREG - Avacta Group PLC - AVA6000 Abstract Release by AACR
AnnouncementRCS - Avacta Group PLC - Investor Webinar
AnnouncementREG - Avacta Group PLC - Update on AVA6000 Phase 1a Clinical Trial Progress
AnnouncementREG - AIM - AIM Notice - 19/03/2024
Announcement